PDK4 Activators
The chemical class of PDK4 activators comprises diverse compounds that intricately modulate the activity of pyruvate dehydrogenase kinase 4 (PDK4), a critical regulator of cellular energy metabolism. PDK4 plays a pivotal role in governing the balance between glycolysis and glucose oxidation by phosphorylating and inactivating pyruvate dehydrogenase (PDH), a key enzyme in the tricarboxylic acid (TCA) cycle. The activation of PDK4 is tightly regulated by various small molecules, offering a nuanced understanding of how cellular metabolism responds to distinct signaling cues. One notable group of PDK4 activators includes dichloroacetate (DCA) and its derivatives, such as dichloroacetophenone (DCAp) and dichloroacetone (DCAc). These compounds directly inhibit PDK isoforms, including PDK4, by promoting PDH activity. By disrupting the phosphorylation-mediated inactivation of PDH, these activators shift cellular metabolism towards enhanced glucose oxidation, emphasizing their potential in rewiring metabolic flux. Another set of PDK4 activators operates indirectly by influencing various cellular pathways. For instance, UK5099, a mitochondrial pyruvate carrier (MPC) inhibitor, alters pyruvate availability, indirectly impacting PDK4. Similarly, 3-mercaptopicolinic acid inhibits glutaminolysis, disrupting the TCA cycle and affecting PDK4 activity.
Compounds like α-cyano-4-hydroxycinnamate and tolbutamide showcase the intricate interplay between PDK4 and cellular energy sensing mechanisms. α-cyano-4-hydroxycinnamate, an inhibitor of monocarboxylate transporter (MCT), indirectly influences PDK4 by altering lactate/pyruvate ratios. Tolbutamide, on the other hand, modulates PDK4 through ATP-sensitive potassium (KATP) channels, linking ion channel activity to PDK4-mediated regulation. Furthermore, the PDK4 activator CPI-613, a lipoate derivative, targets mitochondrial enzymes, providing a unique perspective on mitochondrial metabolism's role in regulating PDK4. This exemplifies the potential of mitochondrial interventions as a strategy to modulate PDK4 activity. In conclusion, the chemical class of PDK4 activators encompasses a spectrum of compounds that act either directly on PDK isoforms or indirectly through the intricate modulation of cellular pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dichloroacetic acid | 79-43-6 | sc-214877 sc-214877A | 25 g 100 g | $61.00 $128.00 | 5 | |
Dichloroacetate inhibits PDK4 indirectly by promoting pyruvate dehydrogenase (PDH) activity. DCA inhibits PDK isoforms, shifting the balance towards active PDH. This leads to increased conversion of pyruvate to acetyl-CoA, preventing PDK4-mediated inhibition of PDH and promoting glucose oxidation. | ||||||
UK 5099 | 56396-35-1 | sc-361394 sc-361394A | 10 mg 50 mg | $236.00 $987.00 | 5 | |
UK5099 is a chemical inhibitor of mitochondrial pyruvate carrier (MPC), indirectly impacting PDK4. By inhibiting MPC, UK5099 disrupts mitochondrial pyruvate import, altering the availability of pyruvate for PDK4. This highlights the interconnected regulation between MPC and PDK4, influencing cellular energy metabolism. | ||||||
α-Cyano-4-hydroxycinnamic acid | 28166-41-8 | sc-254923 | 2 g | $43.00 | 2 | |
α-cyano-4-hydroxycinnamate inhibits monocarboxylate transporter (MCT), indirectly influencing PDK4. MCT inhibition alters lactate transport, affecting the lactate/pyruvate ratio. This change in substrate availability modulates PDK4 activity, emphasizing the regulatory role of substrate availability in the modulation of PDK4-mediated control over pyruvate dehydrogenase. | ||||||
3-Mercaptopicolinic Acid, Hydrochloride | 320386-54-7 | sc-206655 | 1 g | $302.00 | 7 | |
3-Mercaptopicolinic acid inhibits PDK4 indirectly through interference with glutaminolysis. By inhibiting glutaminase, it limits the availability of glutamine-derived alpha-ketoglutarate. This disrupts the TCA cycle and alters metabolic substrates, influencing PDK4 activity. This showcases the intricate crosstalk between glutaminolysis and PDK4-mediated regulation of pyruvate dehydrogenase. | ||||||
DHEA | 53-43-0 | sc-202573 | 10 g | $111.00 | 3 | |
DHEA activates AMP-activated protein kinase (AMPK), indirectly impacting PDK4. AMPK activation promotes cellular energy balance, influencing PDK4-mediated inhibition of PDH. DHEA, as an AMPK activator, provides a unique avenue to modulate PDK4 activity through upstream signaling events, revealing the intricate interplay between hormonal regulation and cellular energy metabolism. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Etomoxir inhibits carnitine palmitoyltransferase-1 (CPT-1), indirectly affecting PDK4. By blocking fatty acid transport into mitochondria, Etomoxir alters substrate availability and metabolic flux, influencing PDK4 activity. This exemplifies the interplay between fatty acid oxidation and glucose metabolism, showcasing how modulating one aspect of cellular metabolism can impact the regulatory network involving PDK4. | ||||||
Tolbutamide | 64-77-7 | sc-203298 | 5 g | $44.00 | 2 | |
Tolbutamide indirectly influences PDK4 through ATP-sensitive potassium (KATP) channels. By inhibiting KATP channels, Tolbutamide alters cellular energy status, impacting PDK4-mediated regulation of PDH. This highlights the link between cellular energy sensing mechanisms and PDK4 activity, providing insights into how pharmacological modulation of ion channels can affect cellular metabolic pathways involving PDK4. | ||||||
1,3-Dichloroacetone | 534-07-6 | sc-237720 | 10 g | $42.00 | ||
Dichloroacetone (DCAc) is another derivative of dichloroacetate (DCA) and inhibits PDK isoforms, including PDK4. Similar to DCA, DCAc promotes PDH activity by inhibiting PDKs, disrupting the PDK4-mediated inhibition of PDH. This further emphasizes the efficacy of chemical derivatives in selectively targeting specific components of metabolic pathways, offering potential tools for precise modulation of PDK4 activity. | ||||||
CPI-613 | 95809-78-2 | sc-482709 | 10 mg | $131.00 | 4 | |
CPI-613 is a lipoate derivative that indirectly influences PDK4 by targeting mitochondrial metabolism. By inhibiting key mitochondrial enzymes, CPI-613 disrupts metabolic pathways, impacting PDK4 activity. This highlights the potential of targeting mitochondrial metabolism as a strategy to modulate PDK4-mediated regulation of pyruvate dehydrogenase, offering insights into novel approaches for metabolic intervention. | ||||||